贝佩多酸和他类药物的心血管益处比较
A Michael Lincoff1, Kausik K Ray2, William J Sasiela3
1Department of Cardiovascular Medicine and Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland Clinic, Cleveland, Ohio, USA.
Journal of the American College of Cardiology
|July 3, 2024
概括
班佩多酸显著降低了LDL-C,并减少了对他类药物不耐受患者的心血管事件. 它在降低心血管风险方面的有效性相当于每单位降低LDL-C的他类药物.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 在CLEAR Outcomes试验中,bempedoic酸在对他类药物不耐受的患者中减少了21%的LDL-C和13%的重大心血管不良事件.
- 这项研究旨在比较bempedoic酸与他类药物的心血管益处,以每LDL-C降低为基础.
研究的目的:
- 为了确定使用贝佩多酸降低LDL-C和降低心血管风险是否与他类药物相似,当LDL-C变化按单位标准化时.
- 将胆固醇治疗试验者协作 (CTTC) 方法应用于CLEAR Outcomes试验数据.
主要方法:
- 利用了来自CLEAR Outcomes试验中的13970名患者的数据.
- 应用CTTC方法,将主要血管事件定义为心血管死亡,心肌梗塞,中风或再血管化的复合物.
- 对于CTTC定义的终点来说,标准化危险比率 (HRs) 与LDL-C降低1 mmol/L相比.
主要成果:
- 班佩多酸显示,主要血管事件的相对减少率为15% (HR:0.85;95%CI:0.77-0.94).
- 当正常化每1mmol/L的LDL-C降低时,HR为0.75 (95% CI:0.63-0.90),这与CTTC的0.78的他类药物率比率相当.
- 对于大冠状动脉事件,非致命性心肌梗塞和冠状动脉再血管化,观察到类似的正常化风险降低是bempedoic酸和他类药物.
结论:
- 用贝佩多酸实现的心血管风险降低类似于他类药物的LDL-C同等降低.
- 班佩多酸在对他类药物不耐受的患者中提供了与他类药物相比的心血管益处,每单位的LDL-C降低.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
628
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
628
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
430
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
430
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514